ObjectiveTo report non‐infectious adverse events associated with transperineal prostate biopsy (TPBx) performed under local anaesthesia (LA) in an outpatient setting.Patients and methodsThis study reports secondary outcomes from the Norwegian arm of the prospective NORAPP study (ClinicalTrials.gov identifier NCT04146142) and included all patients referred for prostate biopsy from November 2019 to February 2021. Transperineal magnetic resonance imaging‐transrectal ultrasonography fusion TPBx were taken using 40 mL 1% lidocaine with 4 mL of 8.4% sodium bicarbonate placed in the perineal skin, under the prostatic apex, in the m. levator ani bilaterally, and along the path of the needle. Follow‐up using patient‐reported questionnaires was done immediately after TPBx, and after 2 weeks and 2 months. Pain was reported using a visual analogue scale (VAS) during placement of the LA, and during and after TPBx. Haematuria and acute urinary retention (AUR) rates were recorded.ResultsWe included 402 patients, and the response rate was 99.8% (401/402). The median (interquartile range [IQR]) age was 69 (63–74) years, the prostate volume was 40 (27–58) mL, the prostate‐specific antigen level was 7.0 (4.5–11) ng/mL, and the number of biopsy cores taken was 8 (6–10). The median (IQR) VAS pain score was 1 (1–2) during placement of LA, 1 (0–2) during TPBx, and 0 (0–0) after TPBx. Haematuria and AUR rates were 64% (95% confidence interval [CI] 60–69%) and 0.5% (95% CI 0.1–1.8%), respectively. No patients were hospitalised or required after the TPBx surgical intervention.ConclusionTransperineal prostate biopsies can be performed under LA with limited discomfort to the patient and few post‐TPBx adverse events.

中文翻译：

---

局麻下经会阴前列腺活检的非感染性不良事件

目的报告与在门诊局部麻醉 (LA) 下进行的经会阴前列腺活检 (TPBx) 相关的非感染性不良事件。患者和方法本研究报告了前瞻性 NORAPP 研究挪威部门的次要结果（ClinicalTrials.gov 标识符 NCT04146142）并包括 2019 年 11 月至 2021 年 2 月转诊进行前列腺活检的所有患者。经会阴磁共振成像-经直肠超声融合 TPBx 使用 40 mL 1% 利多卡因和 4 mL 8.4% 碳酸氢钠放置在前列腺尖下方的会阴皮肤中， 在他们中。双侧提肛肌，并沿着针的路径。 TPBx 后立即、2 周和 2 个月后使用患者报告的问卷进行随访。在放置 LA 期间以及 TPBx 期间和之后使用视觉模拟评分 (VAS) 报告疼痛。记录血尿和急性尿潴留（AUR）发生率。结果我们纳入了 402 名患者，缓解率为 99.8%（401/402）。中位年龄（四分位距 [IQR]）为 69 (63–74) 岁，前列腺体积为 40 (27–58) mL，前列腺特异性抗原水平为 7.0 (4.5–11) ng/mL，取出的活检核心数量为 8 (6-10)。 LA 放置期间的中位 (IQR) VAS 疼痛评分为 1 (1–2)，TPBx 期间为 1 (0–2)，TPBx 后为 0 (0–0)。血尿和 AUR 发生率分别为 64%（95% 置信区间 [CI] 60-69%）和 0.5%（95% CI 0.1-1.8%）。 TPBx 手术干预后，没有患者住院或需要住院。结论 经会阴前列腺活检可以在 LA 下进行，患者的不适感有限，并且 TPBx 后不良事件很少。